Care about your Liver: Think about Hepatitis

World Hepatitis Day 28th July 2014   Dear All, It is our pleasure to inform you the activities of health systems in different countries have changed the epidemiology of viral hepatitis especially hepatitis B virus infection during recent years. Hepatitis B vaccination is the most effective method to prevent Hepatitis…

Read More

World Hepatitis Day 28th July 2014

Care about your Liver: Think about Hepatitis   World Hepatitis Day, observed on July 28 every year, aims to raise global awareness of hepatitis — a group of infectious diseases known as Hepatitis A, B, C, D, and E — and encourage prevention, diagnosis and treatment. Hepatitis affects hundreds of…

Read More

Dermatology and Liver diseases

Dear All, Dermatology and Liver diseases It is my pleasure to inform you about activities of “Iran Hepatitis Network” (www.hep.ir ). “Iran Hepatitis Network” reaches many of professionals and practitioners in hepatitis in our country. We have developed from different local associations in Iran and we are delighted to share…

Read More

Japan Approves First All-Oral Hepatitis C Treatment

Japan approves a combination of hepatitis C medication that does not require painful injections. Bristol-Myers Squibb announced Monday that Japanese Ministry of Health, Labor and Welfare has cleared a cocktail of daclatasvir and asunaprevir for treatment of patients with genotype 1 chronic hepatitis C virus infection (HCV), including those with…

Read More

Hepatitis C Epidemic in Africa

  The epidemic levels of Hepatitis C virus (HCV) prevalence in Africa is considered one of the most serious health challenges facing African nations by the World Health Organization (WHO). According to Dr. Peter Beyer, Essential Medicines Advisor at WHO, the greatest challenges to fighting HCV in Africa are drug…

Read More

Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza® (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union

 The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza® (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis…

Read More

Lurking Dangers Behind Overuse of Lamivudine to Treat Non-HIV Hepatitis B Patients in Africa.

Author: Kangbai J. Source: Annals of medical and health sciences research. 2013;3(2):296-8. The potent nucleoside analog reverse transcriptase antiretroviral drug lamivudine, which is also called 3TC, is a vital tool in the treatment and management of HIV and acquired immunodeficiency syndrome (AIDS)-related diseases. Using 3TC in combination with other antiretrovirals…

Read More